Browsing by Author "Onat, Ahmet Mesut"
Now showing 1 - 18 of 18
- Results Per Page
- Sort Options
Publication A nationwide experience with the off label use of interleukin 1 targeting treatment in familial mediterranean fever patients(Wiley, 2016-10-01) Akar, Servet; Çetin, Pınar; Kalyoncu, Umut; Karadağ, Ömer; Sarı, İsmail; Çınar, Muhammed; Yılmaz, Sedat; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Balkarlı, Ayşe; Küçükşahin, Orhan; Öner, Sibel Yılmaz; Şenel, Soner; Tufan, Abdurrahman; Direskeneli, Haner; Öksüz, Mustafa Ferhat; Pehlivan, Yavuz; Bayndır, Özün; Keser, Gökhan; Aksu, Kenan; Omma, Ahmet; Kaşifoğlu, Timuçin; Ünal, Ali Uğur; Yıldız, Fatih; Balcı, Mehmet Ali; Yavuz, Şule; Erten, Şükran; Özgen, Metin; Sayarıoğlu, Mehmet; Doğru, Atalay; Çetin, Gözde Yıldırım; Alibaz-Öner, Fatma; Tezcan, Mehmet Engin; Pamuk, Ömer Nuri; Önen, Fatos; Öksüz, Mustafa Ferhat; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; JXF-7598-2024; AAG-8227-2021Item Behçet disease with vascular involvement: Effects of different therapeutic regimens on the incidence of new relapses(Lippincott Williams & Wilkins, 2015-02) Öner, Fatma Alibaz; Karadeniz, Aslı; Yılmaz, Sema; Balkarlı, Ayşe; Kimyon, Gezmiş; Yazıcı, Ayten; Çınar, Muhammet; Yılmaz, Sedat; Yıldız, Fatih; Bilge, Şule Yaşar; Bilgin, Emre; Omma, Ahmet; Çetin, Gözde Yıldırım; Çağatay, Yonca; Karaaslan, Yaşar; Sayarlıoğlu, Mehmet; Kalyoncu, Umut; Karadağ, Ömer; Kaşifoğlu, Timuçin; Erken, Eren; Pay, Salih; Çefle, Ayşe; Kısacık, Bünyamin; Onat, Ahmet Mesut; Çobankara, Veli; Direskeneli, Haner; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; AAG-7155-2021; AAG-8227-2021; 55646165400; 13205593600Vascular involvement is one of the major causes of mortality and morbidity in Behcet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 +/- 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired. VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. Asecond vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments. We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.Publication Clinical features of takayasu's arteritis from an inception cohort: Early disease is characterized by 'systemic inflammation'(Wiley, 2016-10-01) Alibaz-Öner, Fatma; Ünal, Ali Uğur; Onat, Ahmet Mesut; Kısacık, Bünyamin; Zengin, Orhan; Karadağ, Ömer; Erden, Abdulsamet; Yarkan, Handan; Akar, Servet; Yıldız, Fatih; Erken, Eren; Özer, Hüseyin; Omma, Ahmet; Özbalkan, Zeynep; Karaaslan, Yaşar; Bes, Cemal; Öner, Sibel Yılmaz; Kanıtez, Nilüfer Alpay; Bayndır, Özün; Yavuz, Şule; Düzgün, Nursen; Tufan, Ayşe Nur; Dalkılıç, Ediz; Yoshifuji, Hajime; Tufan, Abdurrahman; Akyol, Lütfi; Öztürk, Mehmet Akif; Sayarlıoğlu, Mehmet; Aksu, Kenan; Keser, Gökhan; Kiraz, Sedat; Pamuk, Ömer Nuri; Önen, Fatoş; Direskeneli, Haner; Tufan, Ayse Nur; DALKILIÇ, HÜSEYİN EDİZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; GHE-4236-2022; CMF-4757-2022Publication Disease activity indices and body mass index: Cross-sectional analysis of a large psoriatic arthritis cohort(Wiley, 2015-10-01) Kalyoncu, Umut; Bayndar, Ozun; Yilmazer, Barış; Dalkılıç, Hüseyin Ediz; Aksu, Kenan; Öksüz, Mustafa Ferhat; Tarhan, E. Figen; Can, Meryem; Küçükşahin, Orhan; Kimyon, Gezmiş; Akyol, Lütfi; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Omma, Ahmet; Bakırlı, Duygu Ersözlü; Özişler, Cem; Gönüllü, Emel; Pehlevan, Seval; Solmaz, Dilek; Çınar, Muhammet; Çetin, Gözde; Tufan, Abdurrahman; Tufan, Müge Aydın; Kılıç, Levent; Erten, Şükran; Kaşifoğlu, Timuçin; Kobak, Şenol; Şenel, Soner; Akar, Servet; Özgen, Metin; Kasapoğlu-Günal, Esen; Yazısız, Veli; Yılmaz, Sedat; Dönmez, Salim; Doğan, İsmail; Köseoğlu, Hamide Kart; Erbasan, Funda; Yıldız, Fatih; Beş, Cemal; Balkarlı, Ayşe; Şahin, Ali; Mercan, Rıdvan; Arslan, Fatoş; Doğru, Atalay; Pay, Salih; Yavuz, Şule; Çakır, Necati; Kabasakal, Yasemin; Aydın, Sibel Z.; DALKILIÇ, HÜSEYİN EDİZ; CMF-4757-2022Publication Identification of susceptibility loci for takayasu arteritis through a large multi-ancestral genome-wide association study(Cell Press, 2021-01-07) Ortiz-Fernandez, Lourdes; Saruhan-Direskeneli, Guher; Alibaz-Oner, Fatma; Kaymaz-Tahra, Sema; Coit, Patrick; Kong, Xiufang; Kiprianos, Allan P.; Maughan, Robert T.; Aydin, Sibel Z.; Aksu, Kenan; Keser, Gokhan; Kamali, Sevil; Inanc, Murat; Springer, Jason; Akar, Servet; Onen, Fatos; Akkoc, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadag, Omer; Kiraz, Sedat; Forbess, Lindsy; Langford, Carol A.; McAlear, Carol A.; Ozbalkan, Zeynep; Yavuz, Sule; Cetin, Gozde Yildirim; Alpay-Kanitez, Nilufer; Chung, Sharon; Ates, Askin; Karaaslan, Yasar; McKinnon-Maksimowicz, Kathleen; Monach, Paul A.; Ozer, Huseyin T. E.; Seyahi, Emire; Fresko, Izzet; Cefle, Ayse; Seo, Philip; Warrington, Kenneth J.; Ozturk, Mehmet A.; Ytterberg, Steven R.; Cobankara, Veli; Onat, Ahmet Mesut; Duzgun, Nursen; Bicakcigil, Muge; Yentur, Sibel P.; Lally, Lindsay; Manfredi, Angelo A.; Baldissera, Elena; Erken, Eren; Yazici, Ayten; Kisacik, Bunyamin; Kasifoglu, Timucin; Dalkilic, Ediz; Cuthbertson, David; Pagnoux, Christian; Sreih, Antoine; Reales, Guillermo; Wallace, Chris; Wren, Jonathan D.; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Sun, Ying; Chen, Huiyong; Grayson, Peter C.; Tombetti, Enrico; Jiang, Lindi; Mason, Justin C.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; 0000-0002-0247-4280; 0000-0003-0660-764X; 0000-0003-4153-903X; 0000-0001-7289-1816; 0000-0002-6376-5583; 0000-0002-3734-1242; 0000-0002-6341-2622; 0000-0002-3718-171X; 0000-0002-8270-2617; 0000-0003-1372-1555; 0000-0003-1185-5816; 0000-0003-4937-0515; 0000-0001-8764-4543; 0000-0003-4965-2918; 0000-0002-8914-9690; 0000-0001-7708-2487; 0000-0002-4530-7167; 0000-0002-7054-1203; 0000-0003-2167-4509; 0000-0002-3785-9834; 0000-0001-6287-9549; 0000-0002-7864-0185; 0000-0001-9993-3916; 0000-0001-9755-1703; 0000-0003-2776-3545; 0000-0003-1123-1464; 0000-0002-7122-9713; 0000-0001-7783-1660; 0000-0001-9284-7345; 0000-0003-2598-5806; GPP-1272-2022; CAG-1626-2022; ISU-1002-2023; D-2668-2012; AAA-6647-2020; AAT-3653-2020; HLH-8218-2023; AAT-3636-2020; KLZ-4006-2024; W-7332-2019; D-9870-2011; GOJ-7451-2022; C-4612-2015; KHW-8303-2024; AAD-5448-2019; AAA-8970-2021; P-4517-2015; L-1241-2015; HJI-6996-2023; JFJ-3399-2023; AAB-3576-2020; C-7018-2014; K-5378-2018Takayasu arteritis is a rare inflammatory disease of large arteries. We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 affected individuals) from five different populations. We discovered HLA risk factors and four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chr13q21 and reinforced IL12B, PTK2B, and chr21q22 as robust susceptibility loci shared across ancestries. Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a potential causal gene for chr21q22 association. We also identified >60 candidate loci with suggestive association (p < 5 x 10(-s)) and devised a genetic risk score for Takayasu arteritis. Takayasu arteritis was compared to hundreds of other traits, revealing the closest genetic relatedness to inflammatory bowel disease. Epigenetic patterns within risk loci suggest roles for monocytes and B cells in Takayasu arteritis. This work enhances understanding of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new therapeutic targets.Publication Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu Arteritis in a genome-wide association study(Wiley, 2015-05-01) Renauer, Paul A.; Saruhan-Direskeneli, Guher; Coit, Patrick; Adler, Adam; Aksu, Kenan; Keser, Gökhan; Alibaz-Öner, Fatma; Aydın, Sibel Z.; Kamali, Sevil; İnanç, Murat; Carette, Simon; Cuthbertson, David; Hoffman, Gary S.; Akar, Servet; Önen, Fatoş; Akkoç, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadağ, Ömer; Kiraz, Sedat; Langford, Carol A.; Maksimowicz-McKinnon, Kathleen; McAlear, Carol A.; Özbalkan, Zeynep; Ateş, Aşkın; Karaaslan, Yaşar; Düzgün, Nursen; Monach, Paul A.; Özer, Hüseyin T. E.; Erken, Eren; Öztürk, Mehmet A.; Yazıcı, Ayten; Cefle, Ayşe; Onat, Ahmet Mesut; Kısacık, Bünyamin; Pagnoux, Christian; Kaşifoğlu, Timuçin; Seyahi, Emire; Fresko, İzzet; Seo, Philip; Sreih, Antoine G.; Warrington, Kenneth J.; Ytterberg, Steven R.; Cobankara, Veli; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Pamuk, Ömer N.; Tunç, S. Ercan; Dalkılıç, Ediz; Bıçakçıgil, Müge; Yentur, Sibel P.; Wren, Jonathan D.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; DALKILIÇ, HÜSEYİN EDİZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; CMF-4757-2022Objective. Takayasu arteritis is a rare large vessel vasculitis with incompletely understood etiology. This study was undertaken to perform the first unbiased genome-wide association analysis of Takayasu arteritis.Methods. Two independent cohorts of patients with Takayasu arteritis from Turkey and North America were included in our study. The Turkish cohort consisted of 559 patients and 489 controls, and the North American cohort consisted of 134 patients and 1,047 controls of European ancestry. Genotyping was performed using the Omni1-Quad and Omni2.5 genotyping arrays. Genotyping data were subjected to rigorous quality control measures and subsequently analyzed to discover genetic susceptibility loci for Takayasu arteritis.Results. We identified genetic susceptibility loci for Takayasu arteritis with a genome-wide level of significance in IL6 (rs2069837) (odds ratio [OR] 2.07, P = 6.70 x 10(-9)), RPS9/LILRB3 (rs11666543) (OR 1.65, P = 2.34 x 10(-8)), and an intergenic locus on chromosome 21q22 (rs2836878) (OR 1.79, P = 3.62 x 10(-10)). The genetic susceptibility locus in RPS9/LILRB3 lies within the leukocyte receptor complex gene cluster on chromosome 19q13.4, and the disease risk variant in this locus correlates with reduced expression of multiple genes including the inhibitory leukocyte immunoglobulin-like receptor gene LILRB3 (P = 2.29 x 10(-8)). In addition, we identified candidate susceptibility genes with suggestive levels of association (P < 1 x 10(-5)) with Takayasu arteritis, including PCSK5, LILRA3, PPM1G/NRBP1, and PTK2B.Conclusion. Our findings indicate novel genetic susceptibility loci for Takayasu arteritis and uncover potentially important aspects of the pathophysiology of this form of vasculitis.Item The IL-33 gene is related to increased susceptibility to systemic sclerosis(Springer Heidelberg, 2015-12-23) Koca, Süleyman Serdar; Kara, Murat; Alibaz-Öner, Fatma; Öztuzcu, Serdar; Yılmaz, Neslihan; Çetin, Gözde Yıldırım; Kısacık, Bünyamin; Özgen, Metin; Pamuk, Ömer Nuri; Direskeneli, Haner; Sayarlıoğlu, Mehmet; Onat, Ahmet Mesut; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021; 13205593600Systemic sclerosis (SSc) is a chronic inflammatory disease characterized by widespread fibrosis of the skin and several visceral organs. The pro-fibrotic potential of interleukin (IL)-33 has been demonstrated by in both in vitro and in vivo settings; moreover, increased level of IL-33 has also been reported in patients with SSc. Therefore, the aim of the present study was to detect the potential association of IL-33 gene polymorphisms on the susceptibility of SSc. A total of 300 SSc patients and 280 healthy controls (HC) were enrolled in this multicentric preliminary candidate gene study. DNA samples were harvested using an appropriate commercial DNA isolation kit. Four single nucleotide polymorphisms (SNPs) of IL-33 gene (rs7044343, rs1157505, rs11792633 and rs1929992) were genotyped using the appropriate commercial primer/probe sets on real-time PCR. There was no significant difference in terms of the allelic distributions and minor allele frequencies of evaluated four IL-33 polymorphisms between the SSc and HC groups (P > 0.05 for all). Moreover, the genotypic distributions of rs1157505, rs11792633 and rs1929992 polymorphisms were not significantly different (P > 0.05 for all). However, CC genotype of rs7044343 SNP was significantly higher in the SSc group compared to the HC group (P = 0.013, OR 1.75, 95 % CI 1.12-2.72). This preliminary candidate gene study demonstrates that rs7044343 polymorphism of IL-33 gene is associated with the susceptibility to the SSc in Turkish population. It may be suggested that IL-33 gene may be a candidate gene to research in SSc.Item Impacts of Anti-TNF treatment on improvement in work place and household productivity in patients with psoriatic arthritis(Wiley, 2016-10) Karadağ, Ömer; Onat, Ahmet Mesut; Küçükşahin, Orhan; Kaşifoğlu, Timuçin; Kısacık, Bünyamin; Pamuk, Ömer Nuri; Yılmaz, Neslihan; Koca, Süleyman Serdar; Yazısız, Veli; Ocakcı, Pınar Talu; Sayarlıoğlu, Mehmet; Terzioğlu, Ender; Erten, Sükran; Kalyoncu, Umut; Dalkılıç, Ediz; Öksüz, Mustafa Ferhat; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; CMF-4757-2022; INW-5232-2023Item Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis(Springer, 2015-11-17) Yolbaş, Servet; Çetin, Gözde Yıldırım; Alibaz, Fatma Öner; Çağatay, Yonca; Yılmaz, Neslihan; Öztuzcu, Serdar; Dönmez, Salim; Özgen, Metin; Koca, Süleyman Serdar; Pamuk, Ömer Nuri; Sayarlıoğlu, Mehmet; Kısacık, Bünyamin; Direskeneli, Haner; Demiryürek, Abdullah Tuncay; Onat, Ahmet Mesut; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; AAG-8227-2021; 13205593600Systemic sclerosis (SSc) is a disease characterized by inflammation, vascular abnormalities and fibrosis. The role of Rho/Rho-kinase pathway was demonstrated in the pathogenesis of fibrosis, inflammation and vascular abnormalities. This study was aimed to investigate the relation between SSc and Rho/Rho-kinase gene polymorphisms. The study included 339 patients with SSc and 302 healthy subjects who were apparently healthy and at similar age and gender. Genotype distributions and allele frequencies were detected by using Chi-square test or Fisher's exact Chi-square test between groups, and the haplotype analysis was applied using online program (SHEsis). Significant association was found in a polymorphism in the ROCK1 gene (rs35996865), a polymorphism in ROCK2 gene (rs10178332), a polymorphism in RhoA gene (rs2177268) and two polymorphisms in RhoC gene (rs11102522 and rs11538960) with SSc disease (p < 0.0022). In this study, association between SSc disease and Rho/Rho-kinase gene polymorphisms was investigated for the first time; significant associations between ROCK1, ROCK2, RhoA and RhoC gene polymorphisms and SSc disease were demonstrated. The results strongly suggest that this SNP may be an important risk factor for development of SSc. However, further validation of these findings in an independent cohort is necessary.Publication Isotretinoin-induced spondilartropathy-related symptoms: A prospective study(Wiley, 2015-10-01) Kısacık, Bünyamin; Kayıran, Nuriye; Zengin, Orhan; Kalem, Ali; Kimyon, Gezmis; Kılınç, Emine Özkul; Kırtak, Necmettin; Onat, Ahmet Mesut; Pehlivan, Yavuz; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0002-6207-8749; AAG-8227-2021Item Isotretinoin-induced spondyloarthropathy-related symptoms: A prospective study(Journal of Rheumatology Publishing Company, 2015-11) Alkan, Samet; Kayıran, Nuriye; Zengin, Orhan; Kalem, Ali; Kimyon, Gezmiş; Kılınç, Emine Özkul; Kırtak, Necmettin; Onat, Ahmet Mesut; Kısacık, Bünyamin; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; 0000-0002-1201-8836; AAG-8227-2021; 13205593600Objective. Acne vulgaris is a chronic inflammatory disease involving the pilosebaceous unit of the skin. Isotretinoin is a systemic retinoid that is often used as an effective treatment option for severe and treatment-resistant acne. Isotretinoin may also cause rheumatologic symptoms. The aim of this prospective observational study was to present followup results regarding the rheumatologic symptoms of patients who received systemic therapy for the treatment of acne (isotretinoin and tetracycline). Methods. For inclusion in the study, all consecutive patients with acne who were aged > 18 years were evaluated by the same dermatologist. The first 42 consecutive patients were included in the isotretinoin group, and after matching for age and sex, 32 consecutive patients were included in the tetracycline group. Isotretinoin treatment was planned as an average dose of 30 mg daily and a total dose of 120-150 mg/kg for 4-6 months. The patients were administered a dose of 1 g/day of tetracycline as 2 equal doses for 3 months. Results. Forty-two patients diagnosed with acne vulgaris were treated with isotretinoin 20.6 ± 4.4 (male/female: 17/22), and 32 patients were treated with tetracycline 20.6 ± 2.7 (male/female: 8/24). There was no significant difference between the 2 groups with respect to age and sex. Unilateral Achilles enthesopathy developed in 3 patients, whereas both Achilles enthesopathy and unilateral sacroiliitis developed in 1 patient. Inflammatory back pain developed in 6 patients in the isotretinoin group. Conclusion. To our knowledge, this was the first prospective observational study that assessed the rheumatologic symptoms of isotretinoin treatment. The spondyloarthropathy findings were identified in 23.1% of the patients who used isotretinoin.Item Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis(Springer/Plenum Publishers, 2014-02) Soydinç, Serdar; Türkbeyler, İbrahim Halil; Soylu, Gülçimen; Göktepe, Mehmet Fatih; Bilici, Muhammed; Zengin, Orhan; Kısacık, Bünyamin; Onat, Ahmet Mesut; Pehlivan, Yılmaz; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; AAG-8227-2021; 13205593600The predictors for the development of cardiovascular diseases and peripheral arterial diseases in patients with systemic sclerosis (SSc) were not clearly established, and there is no specific study conducted to investigate the mean platelet volume (MPV) levels in SSc patients. Therefore, this study evaluates the MPV levels in SSc and possible relationship between SSc, its clinical features and activity/severity scores, and MPV. In total, 76 SSc patients (67 women and 9 men, mean age 50.44 +/- 13.21 years) diagnosed according to the classification criteria of the American College of Rheumatology and 45 healthy volunteers were enrolled into study. Data relating to anamnesis, physical examination, MPV, erythrocyte sedimentation rate, C-reactive protein levels, electrocardiography, echocardiography, high-resolution computerized tomography findings, complaints, and treatment processes were recorded into the database. Of the total cases, 17 had (22.3 %) cardiac involvement, 45 had gastrointestinal involvement (59.2 %), 47 had (61.8 %) lung involvement, 31 (32 %) had finger flexion deformity, and 27 (35.5 %) had digital ulcers at the fingertips. The mean MPV levels of SSc patients were significantly higher than those of the control group (p = 0.008). The mean MPV levels of SSc patients with cardiac involvement, digital ulcers, and gangrene presence were significantly high, and lower in Ilomedin-receiving patients than in the Ilomedin naives (p < 0.05). A negative relationship was discovered between the mean MPV levels, Valentini score, and Disease Severity Index of the patients with systemic sclerosis (p = 0.006, r = -0.310; p = 0.047, r = -0.229). MPV levels were significantly elevated in SSc patients and they were negatively correlated with disease activity scores. Increased MPV levels would be a predictive marker in the diagnosis of macrovascular and microvascular disease involvement in SSc patients.Item Mi-RNA profile of active vascular behcet's patients.(Wiley, 2014-10) Onat, Ahmet Mesut; Gerenli, Ozan; Kısacık, Bünyamin; Ulaşlı, Mustafa; Kimyon, Gezmiş; Öztuzcu, Serdar; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021Item Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension(Springer/Plenum Publishers, 2014-08) Dokuyucu, Recep; Demir, Tuncer; Kaplan, Davut Sinan; Koç, İbrahim; Örkmez, Mustafa; Türkbeyler, İbrahim Halil; Çeribaşı, Ali Osman; Tutar, Ediz; Tayşi, Seyithan; Kısacık, Bünyamin; Onat, Ahmet Mesut; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021; 13205593600Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder that any valuable advance in the management of diseases has crucial importance. The present study aimed to compare the Endothelin1 (ET1) inhibitor bosentan which is regarded as standard therapy with different dose regimens of palosuran which is urotensin-II (UII) inhibitor and explore the discrepancy for mean pulmonary arterial pressure (mPAP), UII, ET1 levels, and pulmonary vascular pathology. Seventy rats were randomly divided into seven groups of ten animals each: group 1 (control group) received the vehicle subcutaneously, instead of monocrotaline (MCT) and vehicle; group 2 (MCT group) received subcutaneous MCT and vehicle; and group 3 (MCT + palosuran 30 mg) received subcutaneous MCT and palosuran. Other groups consist of group 4 (MCT + palosuran 100 mg), group 5 (MCT + bosentan 30 mg), group 6 (MCT + bosentan 100 mg), and group 7 (combination therapy). Serum ET1, UII, mPAP levels, and pulmonary arteriolar pathology of different diameter vessels of all groups have been measured and recorded. The ET1 and UII levels of untreated rats (group 2) were significantly higher than the other groups (p < 0.05). Moreover, mPAP levels of group 2 were significantly higher than the other groups (p = 0.001). Finally, 50-125-mu m diameter of arteriole wall thickness was found to be significantly thicker in monocrotaline group compared to groups 4 and 6 (p < 0.001). Statistical differences of wall thickness/diameter ratios of arteries and arterioles larger than 125 was found to be significant between group 5, group 6, and the control group (p < 0.001). UII inhibitor is at least as effective as standard therapy bosentan. Findings of this study consolidate that palosuran could be a new future promising therapeutic option in PAH.Item Patients' concerns regarding biological agents in rheumatology(Wiley, 2018-01) Kimyon, Gezmiş; Zengin, Orhan; Küçük, Adem; Şahin, Ali; Tomas, Nazmiye; Kısacık, Bünyamin; Akar, Servet; Onat, Ahmet Mesut; Pehlivan, Yavuz; Oruçoğlu, Nurdan; Pehlivan, Seda; Öksüz, Mustafa Ferhat; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; Uludağ Üniversitesi/Sağlık Bilimleri Fakültesi/Hemşirelik Bölümü.; 0000-0002-1670-0672; 0000-0002-8613-5373; B-5037-2017; AAG-8227-2021; ABG-1164-2020; 13205593600; 57199625557; 23095733400; 56016440100; 6506739457ObjectiveThe potential side effects of biological agents may increase the anxiety levels of patients and influence not only their desire to use these therapies but also their concordance to treatment. This study aimed to determine the level and prevalence of drug-related concern in patients treated with biological agents and to acquire additional information regarding the related causes. Materials and MethodsA total of 1134 patients who were using biological agents for at least 3months with a diagnosis of rheumatic diseases were enrolled. General anxiety levels were evaluated using the State-Trait Anxiety Inventory (STAI). ResultsThe most common cause for drug-related concerns was the potential side effects of the drugs (59.5%). Among the potential side effects, cancer risk was the most common cause for concern (40.1%), followed by the risk of tuberculosis activation (30.7%). Anxiety levels were higher in patients who experienced side effects than in other patients, and this difference was statistically significant (P<0.05). STAI trait and state scores were moderately correlated with anxiety levels related to the drug (P<0.001). ConclusionAnxiety related to biological agents may significantly affect the patients' anxiety levels. Awareness regarding the patients' concerns and expectations related to the drug is important to ensure drug adherence and concordance to treatment.Item Sleep quality and factors affecting sleep in elderly patients with rheumatoid arthritis in Turkey(TÜBİTAK, 2015-10-11) Karadakovan, Ayfer; Onat, Ahmet Mesut; Pehlivan, Seda; Pehlivan, Yavuz; Uludağ Üniversitesi/Sağlık Yüksekokulu/Hemşirelik Bölümü.; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0002-1670-0672; B-5037-2017; AAG-8227-2021; ABG-1164-2020; 23095733400; 13205593600Background/aim: Sleep disorders are more common in people with rheumatoid arthritis (RA). We aimed to determine the sleep quality in adult and elderly people with RA and the factors associated with sleep disorders in each group. Materials and methods: The study was conducted with 182 patients (83 elderly and 99 adult patients) diagnosed with RA. Data were collected through a patient identification form including sociodemographic and disease characteristics. The Health Assessment Questionnaire (HAQ) and Pittsburg Sleep Quality Index (PSQI) were used to assess quality of life and sleep. Results: The mean PSQI scores of the elderly group were lower than those of adult subjects (P = 0.055). Patients in remission and those with knee involvement had significantly lower PSQI scores (P < 0.05). Mean PSQI scores of elderly single patients and subjects with sleep disorders and restless leg syndrome were significantly higher (P < 0.05). In elderly subjects, the pain and HAQ scores were positively correlated with the PSQI. Conclusion: Sleep quality of elderly rheumatoid arthritis patients was determined to be worse than that of adults; however, the difference was not statistically different. Factors negatively affecting sleep included pain, joints involved, high disease activity, and restless leg syndrome.Publication The effect of rheumatoid factor and anti-cyclic citrullinated peptide positivity on drug survival of abatacept in patients with rheumatoid arthritis in routine care: The results from turkbio registry(Wiley, 2015-10-01) Ertenli, İhsan; Karadağ, Ömer; Pehlivan, Yavuz; Dalkılıç, Ediz; Onat, Ahmet Mesut; Kısacık, Bünyamin; Can, Gerçek; Akar, Servet; Çapar, Sedat; Kalyoncu, Ümut; Öksüz, Mustafa Ferhat; Tarhan, Emine Figen; Akkoç, Nurullah; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Oksuz, Mustafa Ferhat; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021; CMF-4757-2022; JXF-7598-2024Item Tuberculosis reactivation risk in patients treated with tumor necrosis factor alpha inhibitors: a turkish experience with higher mortality and different background diseases.(Wiley, 2014-10) Kısacık, Bünyamin; Pamuk, Ömer; Onat, Ahmet Mesut; Erer, Burak; Hatemi, Gülen; Özgüler, Yeşim; Kılıç, Levent; Ertenli, İhsan; Can, Meryem; Direskeneli, Haner; Keser, Gökhan; Öksel, Fahrettin; Yılmaz, Sedat; Pay, Salih; Balkarlı, Ayşe; Çobankara, Veli; Çetin, Gözde Yıldırım; Sayarlıoğlu, Mehmet; Cefle, Ayşe; Yazıcı, Ayten; Avcı, Ali Berkant; Terzioğlu, Ender; Özbek, Süleyman; Akar, Servet; Gül, Ahmet; Pehlivan, Yavuz; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021